Forced Degradation Studies: Regulatory Considerations and Implementation - Stress testing studies are conducted to challenge specificity of stability-indicating and impurity- monitoring methods as

ADVERTISEMENT

Forced Degradation Studies: Regulatory Considerations and Implementation
Stress testing studies are conducted to challenge specificity of stability-indicating and impurity- monitoring methods as part of validation protocol.


BioPharm International





The current regulatory guidances governing forced degradation studies of biological pharmaceuticals are extremely general. They itemize broad principles and approaches with few practical instructions. There is no single document that comprehensively addresses issues related to stress studies such as objectives, timing, selection of stress conditions, and extent of degradation. We will attempt to fill that gap by summarizing regulatory guidance for stress studies of biological products and present some examples of their practical applications.

The complexity of biological macromolecules when compared to small molecule therapeutics, differences in manufacturing, and the broad variety of potential degradation pathways lead to special requirements in quality assurance and analytical testing of pharmaceutical proteins. The product-related impurities are molecular variants formed during manufacture, storage, or use, and their properties are different from the desired product with respect to activity, efficacy, and safety.1

Forced degradation studies are designed to generate product-related variants and develop analytical methods to determine the degradation products formed during accelerated pharmaceutical studies and long-term stability studies. Any significant degradation product should be evaluated for potential hazard and the need for characterization and quantitation.2


Michael Kats, Ph.D.
SILENT REGULATIONS Regulatory guidance is open to interpretation. Detailed information and specific instructions for conducting forced degradation studies of biologics and biotechnology products are close to non-existent. The most recent workshop was held in 2001 by the Pharmaceutical Research and Manufacturers of America Analytical Research and Development Steering Committee. The conclusion was that there is little information about strategies and principles. The summary provides useful definitions and general comments about degradation studies, while guidance concerning the scope, timing, and best practices is very general.3 This article shows a way to reduce these generalities to practice.

A one-time forced-degradation study on a single batch is not considered part of the normal stability protocol.4 However, the design of the stress studies and the results are to be provided to regulatory authorities as part of the stability section of the application.5,6

OBJECTIVES OF STRESS STUDIES The best samples of product-related degradants for the specificity evaluation would be retrieved throughout the pharmaceutical stability study.7 The duration of most stability studies makes this ideal situation untenable. Thus, an analyst is faced with the necessity to artificially generate degraded samples.

Forced degradation or stress testing studies are part of the development strategy5 and are also an integral component of validating analytical methods that indicate stability and detect impurities. This relates to the specificity section of the validation studies.5,6 It is important to recognize that forced degradation studies are not designed to establish qualitative or quantitative limits for change in drug substance (DS) or drug product (DP).8

Testing of stressed samples is required to demonstrate the following abilities of analytical techniques employed in stability studies:1,5,9

  • to evaluate stability of DS and DP in solution
  • to determine structural transformations of the drug substance and drug product
  • to detect low concentrations of potential degradation products
  • to detect unrelated impurities in the presence of the desired product and product-related degradants
  • to separate product-related degradants from those derived from excipients and intact placebo.3

The forced degradation studies are also expected

  • to elucidate possible degradation path-ways
  • to identify degradation products that may be spontaneously generated during drug storage and use
  • to facilitate improvements in the manufacturing process and formulations in parallel with accelerated pharm-aceutical studies.

Stress studies may be useful in determining whether accidental exposures to conditions other than normal ranges (e.g., during transportation) are deleterious to the product, and also for evaluating which specific test parameters may be the best indicators of product stability.2,9


blog comments powered by Disqus

ADVERTISEMENT

ADVERTISEMENT

EMA Warns of Falsified Herceptin Vials
April 16, 2014
Mallinckrodt to Acquire Questcor Pharmaceuticals
April 16, 2014
American CryoStem and Rutgers University File Joint Patent on Stem Cell Platform
April 11, 2014
Center for Biologics Evaluation and Research Relocates
April 11, 2014
PhRMA Report Reveals Growth Trajectories and Policy Factors Affecting Biopharmaceutical Growth
April 11, 2014
Author Guidelines
Source: BioPharm International,
Click here